Abbott Laboratories Stock Price, News & Analysis (NYSE:ABT)

$54.64 -0.05 (-0.09 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$54.69
Today's Range$54.32 - $54.85
52-Week Range$37.90 - $56.69
Volume5.10 million shs
Average Volume6.59 million shs
Market Capitalization$95.11 billion
P/E Ratio22.67
Dividend Yield1.94%
Beta1.55

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSE:ABT
CUSIP00282410
Phone+1-847-9376100

Debt

Debt-to-Equity Ratio0.72%
Current Ratio2.69%
Quick Ratio2.26%

Price-To-Earnings

Trailing P/E Ratio22.67
Forward P/E Ratio21.94
P/E Growth2.05

Sales & Book Value

Annual Sales$20.85 billion
Price / Sales4.56
Cash Flow$2.79 per share
Price / Cash19.60
Book Value$12.04 per share
Price / Book4.54

Profitability

Trailing EPS$1.21
Net Income$1.40 billion
Net Margins8.37%
Return on Equity13.98%
Return on Assets6.09%

Miscellaneous

Employees75,000
Outstanding Shares1,740,600,000

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, September 15th. Investors of record on Friday, October 13th will be given a dividend of $0.265 per share on Wednesday, November 15th. This represents a $1.06 annualized dividend and a yield of 1.94%. The ex-dividend date is Thursday, October 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings results on Wednesday, October, 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.65 by $0.01. The healthcare product maker earned $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 earnings per share. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, January, 23rd 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its fourth quarter earnings guidance on Wednesday, October, 18th. The company provided EPS guidance of $0.72-0.74 for the period, compared to the Thomson Reuters consensus estimate of $0.73.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 brokerages have issued 1 year target prices for Abbott Laboratories' shares. Their forecasts range from $42.00 to $68.00. On average, they expect Abbott Laboratories' stock price to reach $57.64 in the next year. View Analyst Ratings for Abbott Laboratories.

What are Wall Street analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "Abbott exceeded the Zacks Consensus Estimate on both earnings and sales front in the third quarter. We are optimistic about the strong and consistent EPD and Medical Devices performance. However, these were to some extent offset by sluggish Nutrition business. The company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved." (10/31/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer (Age 62)
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance (Age 47)
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation (Age 61)
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary (Age 51)
  • Stephen R. Fussell, Executive Vice President - Human Resources (Age 59)
  • Brian J. Blaser, Executive Vice President - Diagnostics Products (Age 52)
  • John M. Capek Ph.D., Executive Vice President - Ventures (Age 55)
  • Robert B. Ford, Executive Vice President - Medical Devices (Age 43)
  • Heather L. Mason, Executive Vice President - Nutritional Products (Age 56)
  • Roger M Bird, Senior Vice President - U.S. Nutrition (Age 60)

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.87%), Macquarie Group Ltd. (0.80%), Flossbach Von Storch AG (0.64%), Diamond Hill Capital Management Inc. (0.64%), Dimensional Fund Advisors LP (0.62%) and Independent Franchise Partners LLP (0.58%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Flossbach Von Storch AG, American Century Companies Inc., Bank of New York Mellon Corp, APG Asset Management N.V., Diamond Hill Capital Management Inc., Dimensional Fund Advisors LP and Boston Partners. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Harding Loevner LP, DSM Capital Partners LLC, Point72 Asset Management L.P., Jennison Associates LLC, Janus Henderson Group PLC, Russell Investments Group Ltd., Crossmark Global Holdings Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $54.64.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $95.11 billion and generates $20.85 billion in revenue each year. The healthcare product maker earns $1.40 billion in net income (profit) each year or $1.21 on an earnings per share basis. Abbott Laboratories employs 75,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 Abbott Park Rd, ABBOTT PARK, IL 60064-3500, United States. The healthcare product maker can be reached via phone at +1-847-9376100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  598 (Vote Outperform)
Underperform Votes:  451 (Vote Underperform)
Total Votes:  1,049
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abbott Laboratories (NYSE:ABT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.722.672.67
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $57.47$57.47$51.94$47.57
Price Target Upside: 3.04% upside3.04% upside1.48% upside5.71% upside

Abbott Laboratories (NYSE:ABT) Consensus Price Target History

Price Target History for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017BarclaysReiterated RatingOverweightN/AView Rating Details
10/19/2017CitigroupReiterated RatingNeutralN/AView Rating Details
10/19/2017BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
10/19/2017CowenSet Price TargetBuy$55.00 -> $68.00N/AView Rating Details
10/19/2017Stifel NicolausBoost Price TargetBuy -> Buy$58.00 -> $63.00N/AView Rating Details
10/19/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$55.00 -> $60.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingBuy$65.00N/AView Rating Details
10/6/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$60.00N/AView Rating Details
10/4/2017Bank of AmericaReiterated RatingBuy$56.00 -> $60.00N/AView Rating Details
9/28/2017Wells Fargo & CompanyBoost Price TargetOutperform$57.00 -> $64.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual WeightLowView Rating Details
6/29/2017GuggenheimInitiated CoverageBuy$58.00LowView Rating Details
6/21/2017BTIG ResearchInitiated CoverageBuy$56.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$45.00LowView Rating Details
8/9/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James FinancialLower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Abbott Laboratories (NYSE:ABT) Earnings History and Estimates Chart

Earnings by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/23/2018$0.73N/AView Earnings Details
10/18/20179/30/2017$0.65$0.66$6.72 billion$6.83 billionViewN/AView Earnings Details
7/20/2017Q2 2017$0.60$0.62$6.63 billion$6.64 billionViewN/AView Earnings Details
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Abbott Laboratories (NYSE:ABT) Earnings Estimates

2017 EPS Consensus Estimate: $2.43
2018 EPS Consensus Estimate: $2.84
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20173$0.59$0.61$0.60
Q3 20173$0.64$0.68$0.66
Q4 20173$0.72$0.73$0.72
Q1 20183$0.56$0.58$0.57
Q2 20183$0.71$0.72$0.72
Q3 20183$0.76$0.77$0.76
Q4 20183$0.78$0.80$0.79
(Data provided by Zacks Investment Research)

Dividends

Abbott Laboratories (NYSE:ABT) Dividend Information

Most Recent Dividend:11/15/2017
Annual Dividend:$1.06
Dividend Yield:1.94%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:87.60% (Trailing 12 Months of Earnings)
42.57% (Based on This Year's Estimates)
37.46% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2017quarterly$0.272.05%10/12/201710/13/201711/15/2017
6/9/2017quarterly$0.272.25%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.272.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.272.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Abbott Laboratories (NYSE ABT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 71.01%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE ABT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/6/2017Miles D WhiteChairmanSell276,886$54.41$15,065,367.26View SEC Filing  
11/30/2017Sharon J BrackenInsiderSell2,188$56.12$122,790.56View SEC Filing  
11/22/2017Alejandro D WellischInsiderSell2,153$55.86$120,266.58View SEC Filing  
11/17/2017Brian J BlaserInsiderSell23,866$55.55$1,325,756.30View SEC Filing  
11/14/2017Daniel Gesua Sive SalvadoriInsiderSell71,157$55.00$3,913,635.00View SEC Filing  
10/23/2017Daniel Gesua Sive SalvadoriEVPSell96,603$56.21$5,430,054.63View SEC Filing  
9/26/2017Daniel Gesua Sive SalvadoriInsiderSell62,460$52.95$3,307,257.00View SEC Filing  
9/22/2017Jaime ContrerasInsiderSell52,700$51.97$2,738,819.00View SEC Filing  
8/16/2017Stephen R FussellInsiderSell196,550$49.50$9,729,225.00View SEC Filing  
8/1/2017Sharon J BrackenInsiderSell2,000$49.16$98,320.00View SEC Filing  
7/27/2017Brian J BlaserInsiderSell15,000$50.00$750,000.00View SEC Filing  
7/25/2017Hubert L AllenInsiderSell4,600$50.79$233,634.00View SEC Filing  
6/15/2017Jared WatkinInsiderSell552$47.97$26,479.44View SEC Filing  
6/8/2017Stephen R FussellInsiderSell196,550$46.00$9,041,300.00View SEC Filing  
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abbott Laboratories (NYSE ABT) News Headlines

Source:
DateHeadline
Abbott Labs to announce dividend increase - NasdaqAbbott Labs to announce dividend increase - Nasdaq
www.nasdaq.com - December 10 at 7:13 AM
Abbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of Shares - NasdaqAbbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of Shares - Nasdaq
www.nasdaq.com - December 10 at 7:13 AM
Abbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of SharesAbbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of Shares
finance.yahoo.com - December 9 at 7:14 AM
Insider Selling: Abbott Laboratories (ABT) Chairman Sells 276,886 Shares of StockInsider Selling: Abbott Laboratories (ABT) Chairman Sells 276,886 Shares of Stock
www.americanbankingnews.com - December 8 at 8:28 PM
Quant Score Make Abbott Laboratories (ABT) a Buy - Investorplace.comQuant Score Make Abbott Laboratories (ABT) a Buy - Investorplace.com
www.investorplace.com - December 5 at 3:22 PM
Abbott Laboratories breached its 50 day moving average in a Bearish Manner : ABT-US : December 5, 2017Abbott Laboratories breached its 50 day moving average in a Bearish Manner : ABT-US : December 5, 2017
finance.yahoo.com - December 5 at 3:22 PM
Abbott to Present at J.P. Morgan Healthcare ConferenceAbbott to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - December 4 at 3:21 PM
Boston Scientific’s Acquisition of Apama: What You Need to KnowBoston Scientific’s Acquisition of Apama: What You Need to Know
finance.yahoo.com - December 4 at 3:21 PM
$7.38 Billion in Sales Expected for Abbott Laboratories (ABT) This Quarter$7.38 Billion in Sales Expected for Abbott Laboratories (ABT) This Quarter
www.americanbankingnews.com - December 3 at 6:26 AM
Abbott Laboratories (ABT) Insider Sells $122,790.56 in StockAbbott Laboratories (ABT) Insider Sells $122,790.56 in Stock
www.americanbankingnews.com - December 1 at 10:26 PM
Abbott Laboratories (ABT) Receives Consensus Recommendation of "Buy" from BrokeragesAbbott Laboratories (ABT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 1 at 6:04 PM
Abbott Laboratories (ABT) Given Consensus Recommendation of "Buy" by AnalystsAbbott Laboratories (ABT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 1 at 6:00 PM
What Analysts Recommend for Bristol-Myers Squibb in November 2017What Analysts Recommend for Bristol-Myers Squibb in November 2017
finance.yahoo.com - December 1 at 3:23 PM
 Analysts Expect Abbott Laboratories (ABT) Will Post Earnings of $0.73 Per Share Analysts Expect Abbott Laboratories (ABT) Will Post Earnings of $0.73 Per Share
www.americanbankingnews.com - December 1 at 2:17 PM
ETFs with exposure to Abbott Laboratories : November 30, 2017ETFs with exposure to Abbott Laboratories : November 30, 2017
finance.yahoo.com - November 30 at 3:21 PM
Boston Scientific Again Delays Heart Valve; Can It Catch Up To Rivals?Boston Scientific Again Delays Heart Valve; Can It Catch Up To Rivals?
finance.yahoo.com - November 29 at 3:21 PM
Abbott Laboratories (ABT) a Buy on Strong Quant Score - Investorplace.comAbbott Laboratories (ABT) a Buy on Strong Quant Score - Investorplace.com
investorplace.com - November 29 at 7:24 AM
Behind Abbott’s Operating Cash Flows and Capital Allocation StrategyBehind Abbott’s Operating Cash Flows and Capital Allocation Strategy
finance.yahoo.com - November 28 at 3:21 PM
Factors of Influence in 2018, Key Indicators and Opportunity within Juno Therapeutics, Abbott Laboratories, Freeport-McMoran, HP, The Trade Desk, and Platform Specialty Products — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within Juno Therapeutics, Abbott Laboratories, Freeport-McMoran, HP, The Trade Desk, and Platform Specialty Products — New Research Emphasizes Economic Growth
finance.yahoo.com - November 28 at 7:54 AM
What Abbott’s Recent Stock Performance Tells UsWhat Abbott’s Recent Stock Performance Tells Us
finance.yahoo.com - November 27 at 3:18 PM
3 Top Diabetes Stocks to Buy Now3 Top Diabetes Stocks to Buy Now
finance.yahoo.com - November 27 at 7:04 AM
What’s Driving Abbott’s Diagnostic Sales and Growth Potential?What’s Driving Abbott’s Diagnostic Sales and Growth Potential?
finance.yahoo.com - November 24 at 9:16 AM
Inside Abbott’s Neuromodulation Business GrowthInside Abbott’s Neuromodulation Business Growth
finance.yahoo.com - November 24 at 9:16 AM
Should You Sell Abbott Laboratories (ABT) At This PE Ratio?Should You Sell Abbott Laboratories (ABT) At This PE Ratio?
finance.yahoo.com - November 23 at 3:20 PM
ValuEngine Upgrades Abbott Laboratories (ABT) to BuyValuEngine Upgrades Abbott Laboratories (ABT) to Buy
www.americanbankingnews.com - November 23 at 12:46 AM
Alejandro D. Wellisch Sells 2,153 Shares of Abbott Laboratories (ABT) StockAlejandro D. Wellisch Sells 2,153 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - November 22 at 8:23 PM
Trade of the Day: Abbott Laboratories (ABT) - Investorplace.comTrade of the Day: Abbott Laboratories (ABT) - Investorplace.com
investorplace.com - November 21 at 3:58 PM
Earnings Momentum Make Abbott Laboratories (ABT) a Buy - Investorplace.comEarnings Momentum Make Abbott Laboratories (ABT) a Buy - Investorplace.com
investorplace.com - November 21 at 3:58 PM
Earnings Momentum Make Abbott Laboratories (ABT) a BuyEarnings Momentum Make Abbott Laboratories (ABT) a Buy
investorplace.com - November 21 at 10:33 AM
Abbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 SharesAbbott Laboratories (ABT) Insider Brian J. Blaser Sells 23,866 Shares
www.americanbankingnews.com - November 20 at 7:37 PM
Roche To Acquire Viewics For Laboratory AnalyticsRoche To Acquire Viewics For Laboratory Analytics
seekingalpha.com - November 20 at 3:45 PM
ETFs with exposure to Abbott Laboratories : November 20, 2017ETFs with exposure to Abbott Laboratories : November 20, 2017
finance.yahoo.com - November 20 at 3:45 PM
Trade of the Day: Abbott Laboratories (ABT)Trade of the Day: Abbott Laboratories (ABT)
investorplace.com - November 20 at 9:00 AM
Daniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) StockDaniel Gesua Sive Salvadori Sells 71,157 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - November 16 at 7:47 PM
How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit SalesHow These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales
finance.yahoo.com - November 16 at 3:35 PM
Breakfast Technical Briefing on Medical Equipment Stocks -- Hologic, Nxstage Medical, Wright Medical, and Abbott LabsBreakfast Technical Briefing on Medical Equipment Stocks -- Hologic, Nxstage Medical, Wright Medical, and Abbott Labs
www.bizjournals.com - November 16 at 10:36 AM
Horizon Pharma PLC (HZNP) and Abbott Laboratories (ABT) Critical ContrastHorizon Pharma PLC (HZNP) and Abbott Laboratories (ABT) Critical Contrast
www.americanbankingnews.com - November 15 at 11:38 AM
High-Level Earnings Momentum Keep Abbott Laboratories (ABT) a BuyHigh-Level Earnings Momentum Keep Abbott Laboratories (ABT) a Buy
investorplace.com - November 14 at 10:28 AM
Abbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.38 BillionAbbott Laboratories (ABT) Expected to Announce Quarterly Sales of $7.38 Billion
www.americanbankingnews.com - November 14 at 6:02 AM
Absolute Reports Fiscal 2018 First Quarter Financial ResultsAbsolute Reports Fiscal 2018 First Quarter Financial Results
www.businesswire.com - November 13 at 5:22 PM
Abbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per ShareAbbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - November 12 at 5:42 PM
ETFs with exposure to Abbott Laboratories : November 9, 2017ETFs with exposure to Abbott Laboratories : November 9, 2017
finance.yahoo.com - November 9 at 4:16 PM
Abbott Laboratories :ABT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Abbott Laboratories :ABT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:21 PM
Abbott Laboratories’ (ABT) High-Level Sales Growth Make it a BuyAbbott Laboratories’ (ABT) High-Level Sales Growth Make it a Buy
investorplace.com - November 7 at 4:49 PM
Abbott Laboratories’ (ABT) High-Level Sales Growth Make it a BuyAbbott Laboratories’ (ABT) High-Level Sales Growth Make it a Buy
investorplace.com - November 7 at 10:04 AM
Abbotts MitraClip OKd in Japan - Seeking AlphaAbbott's MitraClip OK'd in Japan - Seeking Alpha
seekingalpha.com - November 6 at 9:07 PM
Abbotts MitraClip Approved as First Transcatheter Mitral Valve Repair Device in JapanAbbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
finance.yahoo.com - November 6 at 4:07 PM
Abbotts Generic Pharmaceutical Business To Continue Growth Led By Emerging MarketsAbbott's Generic Pharmaceutical Business To Continue Growth Led By Emerging Markets
finance.yahoo.com - November 6 at 4:07 PM
Abbott Laboratories (ABT) Given Consensus Rating of "Buy" by BrokeragesAbbott Laboratories (ABT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 8:08 AM
Heart stents fail to ease chest pain - NYT - Seeking AlphaHeart stents fail to ease chest pain - NYT - Seeking Alpha
seekingalpha.com - November 2 at 3:25 PM

SEC Filings

Abbott Laboratories (NYSE:ABT) SEC Filings

DateFilerForm TypeView
12/08/2017
4:29 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
4:28 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
4:27 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
4:26 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
4:26 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
4:47 PM
Abbott Laboratories (Issuer)
WHITE MILES D (Reporting)
Form 4/A
View Filing
12/01/2017
4:08 PM
Abbott Laboratories (Issuer)
Bracken Sharon J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Abbott Laboratories (NYSE:ABT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abbott Laboratories (NYSE ABT) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.